dc.relation.reference | 1. Huang DP. Epidemiology of nasopharyngeal carcinoma. Ear Nose Throat J 1990; 69:222-225.
2. Department of Health. Cancer Registry Annual Report Republic of China, 1998. Department of Health, The Executive Yuan, Republic of China, 2002.
3. Cheng SH, Jian JJ, Tsai SY, et al. Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 2000;48:1323-30.
4. Cheng SH, Tsai SY, Yen KL, et al. Concomitant radiotherapy and chemotherapy for early stage nasopharyngeal carcinoma. J Clin Oncol 2000;18:2040-5
5. Oh JL, Vokes EE, Kies MS, et al. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol. 2003;14:564-569.
6. Rischin D, Corry J, Smith J, et al. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol 2002;20:1845-1852.
7. Hong RL, Ting LL, Ko JY, et al. Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001;19:4305-4313.
8. Baker SR and Wolfe RA. Prognostic factors of nasopharyngeal malignancy. Cancer.1982; 49:163-169.
9. Liu MT, Hsieh CY, Chang TH, et al. Prognostic factors affecting the outcome of nasopharyngeal carcinoma. Jpn J Clin Oncol 003; 33:501-508.
10. Farias TP, Dias FL, Lima RA, et al. Prognostic factors and outcome for nasopharyngealcarcinoma. Arch Otolaryngol Head Neck Surg 2003; 129:794-799.
11. Chong VF, Fan YF. Detection of recurrent nasopharyngeal carcinoma: MR imaging versus CT. Radiology 1997; 202:463-470.
12. Ng SH, Chang JTC, Ko SF, et al. MRI in recurrent nasopharyngeal carcinoma. Neuroradiology 1999; 41:855-862.
13. Olmi P, Fallai C, Colagrande S, et al. Staging and follow-up of nasopharyngeal carcinoma: magnetic resonance imaging versus computerized tomography. Int J Radiat Oncol Biol Phys 1995; 32:795-800.
14. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is[18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19:414-419.
15. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Onco. 2002; 13:1356-1363.
16. Kosgakoglu L, Cloemen M, Leonard JP, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 2002;43:1018-1027.
17. Jansson T, Westlin JE, Ahlstrom H, et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995;13:1470-1477.
18. Bassa P, Kim EE, Inoue T, et al: Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996;37:931-938.
19. Smith IC, Welch AE, Hutcheon AW, et al. Positron tomography using [18F]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1679-1688.
20. Schelling M, Avril N, Nährig J, et al. Positron emission tomography using [18F]fluorodeoxyglucose for monitoring to primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689-1695.
21. Burcombe RJ, Makris A, Pittam M, et al. Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using[18F]-fluorodeoxyglucose positron emission tomography. Eur J Cancer 2002;38:375-379.
22. Schulte M, Brecht-Krauss D, Werner M, et al: Evaluation of neoadjustvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 1999;40:1637-1643.
23. Franzius C, Bielack S, Flege S, et al. Prognostic significance of 18F-FDG and 99m Tc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med 2002;43:1012-1017.
24. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophgogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-3065.
25. Brücher B, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001;233:300-309.
26. Flamen P, Van Cutsem E, Lerut A, et a. Positron emission tomography for assessment of the response to induction chemotherapy in locally advanced esophageal cancer. Ann Oncol 2002;13:361-368.
27. Ott K, Fink U, Becker K, et al. Prediction of response to properative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003;21:4604-4610.
28. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy to quantitative assessment of glucose use. J Clin Oncol 2003: 21:2651-2657.
29. Lowe VJ, Dunphy FR, Varvares M, et al. Evaluation of chemotherapy response in patients with advanced had and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography. Head Neck 1997;19:666-674.
30. Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 2004;45:56-68.
31. Reisser C, Haberkom U, Dimitrakopulou-Strauss A, et al. Chemotherapeutic management of head and neck malignancies with positron emission tomography. Arch Otolaryngol Head Neck Surg 1995; 121:272-276.
32. Kao CH, ChangLai SP, Chieng PU, et al. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2- deoxyglucose positron emission tomography and comparison with computed tomography. J Clin Oncol 1998; 16:3550-3555.
33. Fischbein NJ, AAssar OS, Caputo GR, et al. Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck. Am J Neuroradiol 1998; 19:1189-1196.
34. Kao CH, Shiau YC, Shen YY, et al. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with technetium-99m methoxyisobutylisonitrile single photon emission computed tompgraphy and conputed tomography. Comparison with 18-fluoro-2-deoxyglucose positron emission tomography. Cancer 2002; 94:1981-1986.
35. Yen RF, Hung RL, Pan MH, et al. 18-fluoro-2-deoxyglucose positron emission tomography in detecting residual/recurrent nasopharyngeal carcinomas and comparison with magnetic resonance imaging. Cancer 2003; 98:283-287.
36. Lee AWM, Foo W, Law SC, Poon YF, O SK, Tung SY, wt al. Staging of nasopharyngeal carcinoma: from Ho’s to the new UICC system. Int J Cancer 1999; 84:179-187.
37. American Joint Committee on Cancer (AJCC). Manual for staging of cancer, sixth edition. Springer, 2002; 35-36.
38. Shanmugaratnam K. Histopahtology of nasopharyngeal carcinoma. Correlations with epideriomolgy, survival rates and other biological characteristics. Cancer 1979; 44:1029-1044.
39. Ng SH, Liu HM, Ko SF, et al. Postreatment imaging of the nasopharynx. Eur J Radiol 2002; 44:82-95.
40. Roychowdhury DG. Tseng AJ, Weinbery V, et al. New prognostic factors in nasopharyngeal carcinoma: tumor angiogenesis and C-erbB2 expression. Cancer 1996; 77:1419-1426.
41. Mould RF, Tai THP. Nasopharyngeal carcinoma: treatments and outcomes in the 20th century. Brit J Radiol 2002; 75:307-339.
42. Di Chiro G. Positron emission tomography using 18F-fluoro-deoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 1986; 22:360-371.
43. Rigo P, Paulus P, Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23:1641-1674.
44. Gallagher BM, Fowler JS, Gutterson NI et al. Metabolic trapping as a principle of radiopharmaceutical design : some factors responsible for the biodistribution of F-18-2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978; 19:1154-1161.
45. Sokoloff L, Reivich M, Kennedy C et al. The (14C)-deoxyglucose method the the mesurement of local cerebral glucose utilization: theroy, procedure and normal values on the conscious and anesthetized albino rat. J neurochem 1977; 28:897-916.
46. Warburg O. On the origin of cancer cells. Science 1956; 123:309-314.
47. Hatanaka M. Transport of sugar in tumor cell membranes. Biochem Biophys Acta 1974; 355:77-104.
48. Hiraki Y, Rosen OM, Birnbaum MJ. Growth factors rapidly induce expression of the glucose transporter gene. J boil chem 1988; 263:13655-13662.
49. Gould MK, aclean CC, Kuschner WG, et al: Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis. JAMA 2001; 285:914-924.
50. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose(FDG) PET in nodal staging. Radiology 1997; 203:795-800.
51. Wahl RL, Cody RL, Hutchnis GD, et al. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2[F-18]2-deoxy-2-fluoro-D-glucose. Radiology 1991; 179:765-770.
52. Price P, Jones T. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. Eur J Cancer 1995; 31A:1924-1927.
53. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodexoyglucose and positron emission tomography: review and 1999 EORTC recommendation. Eur J Cancer 1999;35:1773-1782.
54. Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is[18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19:414-419.
55. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol 2002; 13:1356-1363.
56. Kosgakoglu L, Cloemen M, Leonard JP, Kuji I, Zoe H, and Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 2002; 43:1018-1027.
57. Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, and Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995; 13:1470-1477.
58. Bassa P, Kim EE, Inoue T, Wong FC, Korkmaz M, Yang DJ, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996; 37:931-938.
59. Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, et al. Positron tomography using [18F]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000; 18:1679-1688.
60. Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D, et al. Positron emission tomography using [18F]fluorodeoxyglucose for monitoring to primary chemotherapy in breast cancer. J Clin Oncol 2000; 18:1689-1695.
61. Burcombe RJ, Makris A, Pittam M, Lowe J, Emmott J, and Wong WL. Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography. Eur J Cancer 2002; 38:375-379.
62. Schulte M, Brecht-Krauss D, Werner M, Hartwig E, Sarkar MR, Keppler P, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 1999; 40:1637-1643.
63. Franzius C, Bielack S, Flege S, Sciuk J, Jürgens H, and Schober O. Prognostic significance of 18F-FDG and 99m Tc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med 2002; 43:1012-1017.
64. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19:3058-3065.
65. Brücher B, Weber W, Bauer M, Fink U, Avril N, Stein HJ, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001; 233:300-309.
66. Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G, et al. Positron emission tomography for assessment of the response to induction chemotherapy in locally advanced esophageal cancer. Ann Oncol 2002; 13:361-368.
67. Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, Stein H, et al. Prediction of response to properative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003; 21:4604-4610.
68. Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy to quantitative assessment of glucose use. J Clin Oncol 2003: 21:2651-2657.
69. Lowe VJ, Dunphy FR, Varvares M, Kim H, Wittry M, Dunphy CH, et al. Evaluation of chemotherapy response in patients with advanced had and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography. Head Neck 1997; 19:666-674.
70. Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 2004; 45:56-68.
71. Reisser C, Haberkom U, Dimitrakopulou-Strauss A, Seifert E, and Strauss LG. Chemotherapeutic management of head and neck malignancies with positron emission tomography. Arch Otolaryngol Head Neck Surg 1995; 121:272-276.
72. Rozental JM, Levine RL, Nickles RJ, Dobkin JA. Glucose uptake by gliomas after treatment. Arch Neurol 1989; 46:1302-1307.
73. De Witte O, Hildebrand J, Luxen A, Goldman S. Acute effect of carmustine on glucose metabolism in brain and glioblastoma. Cancer 1994; 74:2836-2842.
74. Fulham MJ, Bruneti A, Aloj H, et al. Decreased cerebral glucose metabolism in patients with brain tumours: an effect of corticosteroids. J Neurosurg 1995; 83:657-664.
75. O’Reilly Sm, newlands ES, Harte RJA, et al. Early changes in tumour glucose metabolism may predict and quantify response of gliomas to chemotherapy: a phase II study using temozolomide. Proc Am Soc Clin Oncol 1995; 14:499.
76. Yen TC, Chang YC, Chan SC, et al. Are dual-phase 18F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes. Eur J Nucl Med Mol Imaging 2005; 32:541-548.
77. Kao CH, Hsieh JF, Tsai SC, et al. Comparison of 18-fluoro-2deoxyglucose positron emission tomography and computed tomography in detection of cervical lymph node metastases of nasopharyngeal carcinoma. Ann Oto Rhinol Laryngol 2000; 109:1130-1134.
78. Ng SH, Chang TC, Chan SC, et al. Nodal metastasee of nasopharyngeal carcinoma: patterns of disease on MRI and FDG PET. Eur J Nucl Med Mol Imaging 2004; 31:1073-1080.
79. Yen TC, Chang JTC, Ng SH, et al. The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx. J Nucl Med 2005; 46:405-410.
80. Change JTC, Chan SC, Yen TC, et al. Nasopharyngeal carcinoma staging by (18)F-Fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys 2005; 62:501-507.
81. Nishioka T, Shiga T, Shirato H, et al. Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys 2002; 53:1051-1057.
82. Tsai MH, Shiau YC, Kao CH, et al. Detection of recurrent nasopharyngeal carcinomas with positron emission tomography using 18-fluoro-2-deoxyglucose in patients with indeterminate magnetic resonance imaging findings after radiotherapy. J Cancer Res Clin Oncol 2002; 128:279-282.
83. Ng SH, Chang JTC, Chan SC, et al. Clinical usefulness of 18F-FDG PET in nasopharyngeal carcinoma patients with questionable MRI findings for recurrence. J Nucl Med 2004; 45:1669-1676.
84. Kaplan ES, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 58:457-481.
85. Goerres GW, Mosna-Firiejczyk K, Steurer J, et al. Assessment of clinical utility of 18F-FDG PET in patients with head and neck cancer: a probability analysis. Eur J Nucl Med Mol Imaging 2003; 30:562-571.
86. Beck JR, Kassirer JP, Pauker SG: A convenient approximation of life expectancy (the “DEALE”): I. Validation of the method. Am J Med 1982a; 73:883-888.
87. Chua DTT, Wei WI, Sham JS, et al. Treatment outcome for synchronous locoregional failures of nasopharyngeal carcinoma. Head Neck 2003;?585-594.
88. Poon D, Yap sp, Wong ZW, et al. Concurrent chemoradiotherapy in locoregionally recurrent nasopharyneal carcinoma. Int J Radiat Oncol Biol Phys 2004; 59:1312-1318.
89. Shin SS, Ahn YC, Lim DH, et al. High dose 3-dimensional re-irradiation for locally recurrent nasopharyngeal cancer. Yonsei Med J 2004; 45:100-106.
90. Higashi K, Anaira CC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? in vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993; 34:414-419.
91. Duhaylongsod FG, Lowe VJ, Patz EF Jr., Vaughn AL, and Coleman RE. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 1995; 60:1348-1352.
92. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, and Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11:2101-2111.
93. Yen RF, Chen ML, Liu FY, Ko SC, Chang YL, Chieng PU, et al. False-positive 2-[F-18]-fluoro-2-deoxy-d-glucose positron emission tomography studies for evaluation of focal pulmonary abnormalities. J Formosan Med Assoc 1998; 97:642-5.
94. Schoder H, Yeung HW, Gonen M, Kraus D and Larson SM. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004; 231:65-72.
95. Goerres GW, von Schulthess GK, Steinert HC. Why most PET of lung and head-and-neck cancer will be PET/CT. J Nucl Med 2004; 45:66S-71S.
96. Dressel S, Grammerstorff J, Schwenzer K, Brinkbaumer K, Schmid R, Pfluger T, et al. [18F]FDG imaging of head and neck tumours: comparison of hybrid PET and morphological methods. Eur J Nucl Med Mol Imaging 2003; 30:995-1003.
97. Bengel FM, Ziegler SI, Avril N, Weber W, Laubenbacher C, Schwaiger M. Whole-body positron emission tomography in clinical oncology: comparison between attenuation-corrected and uncorrected images. Eur J Nucl Med 1997; 24:1091-1098.
98. Mitsuhashi N, Hayakawa K, Hasegawa M, et al. Clinical FDG-PET in diagnosis and evaluation of radiation response of patients with nasopharyngeal tumor. Anticancer Res 1998; 18:2827-2832.
99. Greven KM, Williams DW 3rd, Keyes JW Jr, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 1994; 74:1355-1359.
100. Chaiken L, Rege S, Hoh C, et al. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Int J Radiat Oncol Biol Phys 1993; 27:455-464.
101. Greven KM, Williams DW 3rd, Keyes JW Jr, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 1994; 74:1355-1359.
102. van den Brekel MW, Stel HV, Castelijns JA, et al. Cervical lymph node metastasis: assessment of radiologic criteria. Radiology 1990; 177:379-384.
103. Chua DTT, Sham JST, Kwong DLW, et al. Retropharyngeal lymphadenopathy in patients with nasopharyngeal carcinoma. Cancer 1997; 79:869-877.
104. Bailet JW, Abemayor E, Jabour BA, et al. Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 1992; 102:281-288.
105. Brink I, Klenzner T, Krause T, et al. Lymph node staging in extracranial head and neck cancer with FDG PET –appropriate uptake period and size-dependence of the results. Nuklearmedizin 2002; 41:108-113.
106. Mancuso AA, Drane WE, Mukherji S. The promise FDG in diagnosis and surveillance of head and neck cancer. Cancer 1994; 74:1193-1195.
107. Huang CJ, Leung SW, Lian SL, et al. Patterns of distant metastases in nasopharyngeal carcinoma. Kaohsiung J Med Sci 1996; 12:229-234.
108. Kitagawa Y, Nishizawa S, Sano K, et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 93:202-207
109. Pai M, Park CH, Suh JH, et al. Fluorine-18 fluorodeoxyglucose imaging using dual-head coincidence positron emission tomography without attenuation correction in patients with head and neck cancer. Clin Nucl Med 1999; 24:495-500.
110. Barrington SF, Maisey MN. Skeletal muscle uptake of fluorine-18-FDG: effect of oral diazepam. J Nucl Med 1996; 37:1127-1129.
111. Mukherji SK, Drane WE, Mancuso AA, et al. Occult primary tumors of the head and neck: detection with 2-[F-18]fluoro-2-deoxy-d-glucose SPECT. Radiology 1996; 199:761-766.
112. Hong RL, Lin CY, Tin LL, et al. Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy. Cancer 2004; 100:1429-1437. | en |